Table 2.
Clinical characteristics and laboratory results for acute HEV-infected patients by HEV GT3 subtype.
| Characteristics | HEV GT3 (n = 37) |
HEV GT3c (n = 6) |
HEV GT3e (n = 8) |
HEV GT3f (n = 21) |
p-Value |
|---|---|---|---|---|---|
| Duration of hospitalization, days | 9 (7–11) | 9.5 (8.5–13.25) | 8 (7–8.75) | 10 (6.5–16.5) | 0.28 |
| Duration of symptoms before hospitalization, days | 7 (5–9.5) | 5.5 (2.7–15) | 9 (2.7–13.7) | 7 (5–8) | 0.80 |
| Clinical hepatitis | |||||
| Icteric | 15 (40.5%) | 2 (33.3%) | 3 (37.5%) | 9 (42.8%) | 0.9 |
| Anicteric | 22 (59.5%) | 4 (66.7%) | 5 (62.5%) | 12 (57.1%) | |
| Severe acute hepatitis and/or liver decompensation | 13 (36.1%) | 3 (50%) | 1 (12.5%) | 9 (42.8%) | 0.2 |
| Symptoms | |||||
| Asthenia | 18 (48.6%) | 3 (50% | 4 (50%) | 9 (42.8%) | 0.9 |
| Fever | 12 (32.4%) | 1 (16.7%) | 2 (25%) | 9 (42.8%) | 0.4 |
| Nausea/vomiting | 15 (40.5%) | 2 (33.3%) | 4 (50%) | 7 (33.3%) | 0.7 |
| Diarrhea | 4 (10.8%) | 1 (16.7%) | 1 (12.5%) | 2 (9.5%) | 0.9 |
| Epigastric pain | 13 (35.1%) | 3 (50%) | 6 (75%) | 4 (19%) | 0.01 |
| Arthralgia | 4 (10.8%) | 0 | 3 (37.5%) | 1 (4.8%) | |
| Extra-hepatic manifestations | 11 (29.7%) | 3 (50%) | 0 | 7 (33.3%) | 0.2 |
| Laboratory parameters at peak | |||||
| AST, U/L | 1167 (412.5–2088) |
1587.5 (613.25–3608.25) |
1210.5 (178.25–1912.7) |
1228 (284.5–2211.5) |
0.7 |
| ALT, U/L | 1751 (1.026–2810) |
2100.5 (1013–3629.75) |
1932.5 (525.5–2930) |
1591 (995.5–2736.5) |
0.6 |
| Total bilirubin, mg/dL | 7 (2.3–12.2) |
6.03 (1.4–17.1) |
3.5 (1.4–7.2) |
10 (2.8–19.2) |
0.3 |
| γGT, U/L | 265 (164.5–401.5) |
437 (168.7–646) |
399.5 (202–578.5) |
242 (148.5–336.5) |
0.1 |
| ALP | 317.5 (203.5–577.25) |
261 (165.5–539.7) |
403 (231.7–661.7) |
276 (204–465.7) |
0.6 |
| INR | 1.17 (1.08–1.5) |
1.6 (1.17–2.89) |
1.15 (1.03–1.21) |
1.15 (1.1–1.5) |
0.03 |
Alanine aminotransferase, ALT; aspartate aminotransferase, ASP; γglutammil transferase, γGT; alkaline phosphatase, ALP; international normalized ratio, INR.